Skip to main content
. 2023 Sep 27;30(10):8805–8814. doi: 10.3390/curroncol30100635

Figure 2.

Figure 2

Response to the combined treatment of osimertinib with crizotinib of multiple sections. Computer tomography scan from the chest and liver sections at the time of tumor progression after osimertinib, revealing multiple metastases (January 2021), and after 6 weeks of therapy with crizotinib plus osimertinib, revealing partial remission in both lung and hepatic sites. The reduction can be seen in tumor size (A), pleural effusions (B), and the liver metastatic sites (C and D).